Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.49 |
| ▸ | WNT3A | P56704 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11796769 | 0.94 | KMT2A (0.58) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL2337097 | 0.88 | KMT2A (0.64) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL9419411 | 0.87 | KMT2A (0.69) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL8402203 | 0.85 | KMT2A (0.67) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL16552778 | 0.83 | KMT2A (0.83) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL2235019 | 0.82 | GSK3B (0.63) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL862889 | 0.82 | NPC1 (0.76) | NPC1RAB9AL3MBTL1HSD17B3ALDH1A1 | |
| SCHEMBL4839086 | 0.82 | HSD17B3 (0.71) | KMT2AGSK3BNPC1RAB9AMEN1 | |
| SCHEMBL3689140 | 0.81 | ALDH1A1 (0.52) | KMT2ANPC1RAB9AMEN1L3MBTL1 | |
| SCHEMBL11277802 | 0.80 | GSK3B (0.64) | KMT2AGSK3BNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336698-B2 | Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| EP-3247699-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20170369440-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | EUROAPI GERMANY GMBH (DE) | 2017-12-28 | — | — | US | disclosed |
| WO-2016116555-A1 | Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-07-28 | — | — | WO | disclosed |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8633188-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-5171858-A | Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines | SCHERING A.G. (DE) | 1992-12-15 | — | — | US | disclosed |
| EP-0307814-B1 | TETRACYCLIC QUINAZOLINE DERIVATIVES, PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1992-04-08 | — | — | EP | disclosed |
| US-5030636-A | Treating psychotic disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-5026712-A | Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents | SCHERING AG (DE) | 1991-06-25 | — | — | US | disclosed |
| EP-0399159-A2 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-11-28 | — | — | EP | disclosed |
| EP-0307814-A2 | Tetracyclic quinazoline derivatives, preparation and use | BASF Aktiengesellschaft (DE) | 1989-03-22 | — | — | EP | disclosed |
| US-4596872-A | Imidazo[1,2-a]pyridines, and process for their preparation | SCHERING A.G. (DE) | 1986-06-24 | — | — | US | disclosed |
| US-4358457-A | ANTICONVULSANTS, ANALGESICS, AND MUSCLE RELAXANTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-11-09 | — | — | US | disclosed |
| US-3979444-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3965257-A | DIPHENYL-4-PIPERIDYL-METHANES | RICHARDSON-MERRELL INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336698-B2 | Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile | CYP4B1, CYP3A4, CYP4F2 | KMT2A 1437/4885GSK3B 3853/4885NPC1 3720/4885 |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | KMT2A 1369/4885GSK3B 559/4885NPC1 205/4885 |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | KMT2A 870/4885GSK3B 231/4885NPC1 91/4885 |
| US-20170369440-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(CYCLOPROPANECARBONYL)PHENYL]-2-METHYL-PROPANENITRILE | CYP4B1, CYP3A4, CYP4F2 | KMT2A 1437/4885GSK3B 3853/4885NPC1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.